May 05, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.
May 05, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the focus on BCL-2 inhibitors versus the development of MCL-1 inhibitors for multiple myeloma treatment.
May 02, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, describes clinical trials looking at venetoclax resistance, including the CANOVA study.
May 02, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Oncologists discuss the use of carfilzomib for multiple myeloma and their typical treatment regimens of choice.
April 18, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.
April 18, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Shaji Kumar reviews data from his BELLINI clinical trial studying venetoclax paired with bortezomib and dexamethasone for multiple myeloma treatment.